Type / Class
Equity / American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share
Shares outstanding
41.1M
Number of holders
28
Total 13F shares, excl. options
27.4M
Shares change
-1.28M
Total reported value, excl. options
$137M
Value change
-$13M
Number of buys
16
Number of sells
-7
Price
$5.01

Significant Holders of Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL) as of Q4 2021

33 filings reported holding ACHL - Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share as of Q4 2021.
Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL) has 28 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 27.4M shares of 41.1M outstanding shares and own 66.71% of the company stock.
Largest 10 shareholders include Syncona Portfolio Ltd (11.1M shares), RA CAPITAL MANAGEMENT, L.P. (5.01M shares), BAKER BROS. ADVISORS LP (2.59M shares), Artal Group S.A. (2.26M shares), Redmile Group, LLC (2.09M shares), ORBIMED ADVISORS LLC (1.58M shares), Point72 Asset Management, L.P. (1M shares), PERCEPTIVE ADVISORS LLC (755K shares), Woodline Partners LP (324K shares), and AXA S.A. (283K shares).
This table shows the top 28 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.